Androgen Insensitivity Syndrome with Bilateral Gonadal Sertoli Cell Lesions, Sertoli-Leydig Cell Tumor, and Paratesticular Leiomyoma: A Case Report and First Systematic Literature Review.

Androgen insensitivity syndrome (AIS) is a rare Mendelian disorder caused by mutations of the androgen receptor () gene on the long arm of the X chromosome. As a result of the mutation, the receptor becomes resistant to androgens, and hence, karyotypically male patients (46,XY) carry a female phenotype. Their cryptorchid gonads are prone to the development of several types of tumors (germ cell, sex cord stromal, and others).

Different Patterns of Vascularization in Preinvasive States and at the Initial Stages of Invasive Growth of the Neoplasms.

Tissue samples obtained during surgery from 90 patients with malignant neoplasms of various localizations were studied (the presence of precancerous dysplastic alterations and their transition to invasive cancer in the slides were obligatory condition). In addition to traditional histological methods, immunohistochemical reactions for detection of HIF-1α, GLUT1, CAIX, and CD31 were performed. At the precancerous stage including cancer in situ, progressive signs of reduced blood vessel density and hypoxia were observed.

Stromal Changes in Colon Blastomogenesis Associated with Development of Hypoxia in the Foci of Dysplasia.

We studied the features of reaction of the colon stromal cells (lymphohistiocytic population, fibroblasts, and blood vessels) to the appearance and progression of dysplasia in the colon epithelium against the background of increasing ischemia in the colon mucosa. The morphological material from 92 patients treated for benign processes and colon cancer in 2002-2016 was examined. Common histological methods and a complex immunohistochemical staining were used.

The Problem of Vascularization of Precancerous Lesions of the Colon and Development of Hypoxia at the Incipient Stages of Blastomogenesis.

The features of the blood supply in the colon mucosa during the development of hyperplastic and dysplastic processes, and early neoplastic lesions were studied. The study cohort comprised the material of 92 patients of the N. N.

Combined anti-HER2 and hormonal treatment in a patient with HRHER2 clear-cell uterine carcinoma: A case report.

Clear-cell carcinoma (CCC) of the uterus is an aggressive disease. Current international guidelines on the treatment of uterine carcinomas predominantly cover cancer with endometrioid histology, and clinicians tend to use the same approach for patients with non-endometrioid histology due to the absence of separate guidelines for these rare tumor types. At present, molecular analysis enables the assessment of novel and non-standard treatment options based on the individual characteristics of a tumor.